Portal de Periódicos da CAPES

Protamine sulphate: A review of its effects: Hypersensitivity and toxicity

1989; Elsevier BV; Volume: 3; Issue: 3 Linguagem: Inglês

10.1016/s0950-821x(89)80082-9

1876-472X

Bengt Lindblad,

Electrospun Nanofibers in Biomedical Applications

Despite the improved safety-profile of direct oral anticoagulants (DOACs), bleeding complications remain an important side effect of anticoagulant treatment. Although anticoagulant-specific antidotes are available, an universal anticoagulant reversal agent in case of life-threatening bleeding or emergency surgery is not yet available. Ciraparantag, a synthetic small molecule that inactivates heparins and DOAC, is a promising new reversal agent that has been investigated in phase 2 trials. In this short review we provide an overview of the preclinical and clinical evidence of ciraparantag, and compare strengths and weaknesses of ciraparantag and the currently available anticoagulant reversal strategies.